Previous 10 | Next 10 |
Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard ® DNA test to over 8 million covered lives Lucid Diagnostics Inc. (Nasdaq: LUCD ) (“Lucid”, the “Company”) a commercial-st...
Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study PR Newswire Vault CDMS to manage clinical data for trial involving Barrett's esophagus and esophageal adenocarcinoma patients PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -...
Gainers: Vivakor (VIVK) +91%. Digital World Acquisition (DWAC) +33%. Studio City International Holdings (MSC) +31%. Tempest Therapeutics (TPST) +30%. PAVmed (PAVM) +17%. AppTech Payments (APCX) +16%. Priority Technology Holdings (PRTH) +14%. Fusion Pharmaceuticals (FUSN) +14%. Alkermes ...
Company conference call and webcast at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the Company will host a business update conference call on Thursday, May 12, 2022, ...
Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Gainers: Tilray Brands (TLRY) +15%. Clever Leaves (CLVR) +12%. Ensysce Biosciences (ENSC) +11%. Icosavax (ICVX) +10%. Cullinan Oncology (CGEM) +6%. Losers: Celsion (CLSN) -19%. IMARA (IMRA) -14%. Owlet (OWLT) -12%. PAVmed (PAVM) -10%. Accelerate Diagnos...
Updated American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard ® on samples collected with EsoCheck ® Proposed Medicare Local Coverage Determination published by Palmetto GBA’s MolDX Program trigge...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO,...
PAVmed Inc. (PAVM) Q4 2021 Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Mark...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...